The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Robots are nice
Terribly precise
But much more efficient
Not doing things thrice
Take 3 instruments into the oesophagus? Smart robots use Speedboat F-poem, you know it makes sense!
This is a game changer, a revolution, a coup - "We were thrilled to witness the successful execution of the F-Poem procedure using solely the Speedboat device, a task that traditionally requires three separate instruments. This not only showcases the device's efficiency but also enhances the cost-effectiveness of the procedure, underscoring the economic advantages Creo's technology can deliver"
I don't see training as an issue - they invested heavily in that a while ago, and now it is well established and widespread. The multiple recent use cases are an example of the large number of practitioners already familiar with the tech. The emergence of the mature product, probably close to the final version, makes the case even stronger for hospitals around the world to get on board and reap the substantial benefits. The robotics companies may also have more incentive to invest in integrating the tool into their systems, because they are now dealing with a standardized, mainstream product form. Target for break-even was sometime in 2025 when they last spoke about it. I'm hoping this year will see a constant drip of positive newsflow, including confirmation that that target is visible and static.
I'd say the chances of a bid here are approximately zero. It's basically a family business executing a long-term growth strategy. Far more likely to be acquiring than divesting, imo
The Sunday Times (summarized in The Week):
This “home-grown tech giant” provides accounting, HR and payroll software to small- and medium-sized businesses. Not cheap, but integrating AI into products will put “new boosters” under shares. Buy.
The Daily Telegraph (summarized in The Week):
Shares in the payroll and accounting systems provider have soared 43%, thanks to strong pricing power and recurring revenues. Solid finances will make it easier to scale up and improve efficiencies. Hold. £11.34.
Fund managers Lindsell Train have increased their holding slightly to 5%. Big ticket, get on board, etc
Strange newsflow. It's as if they read my comment a couple of days ago and decided to reply with a whole raft of use cases from the States ( : Surely they knew about this when the previous RNS went out - or did all these procedures happen this week? ( : Anyway, great news that Creo tech is suddenly addressing so many different patient conditions. Shows how quick adoption can happen. With trained eager physicians ready to go, and manufacturing in place, it feels like most of the hard work has been done now and it's time to reap the rewards and move forward with other products. Not quite certain yet, but it really looks like this is the start of a VERY positive step change in this branch of surgery, with Creo right at the heart of it.
No Evanescent, that's not quite correct. The founding Bharti family have always been overwhelming controllers of this company, they own close to 70% of it now, and it's really a offshoot of the Indian parent company. Interesting that they have been increasing their stake slightly this month though - presumably they think it is undervalued
It's a slightly confusing update. They got approval from the FDA last month, and fast-tracked for approval in Europe, but now the first use case is in the UK. From previous updates you might have thought the US would be first? Anyway the big news is they are into manufacturing now, so the revenues from this excellent new product should start rolling in next year, from both markets.
And some more - 290,000 new shares for 195.58p each. That's a handy chunk of change to diversify into what feels like a depressed market
Another great T.U. from Bloomers - revenue and profit on track to shred market expectations again. Probably the best managed, most consistent group in their sector. Plenty in the pipeline for further growth. Fantastic to see nurtured and supported talent developing into world class, prize-winning, screen-adapted authors.
CMR raised money in September:
https://www.linkedin.com/posts/james-staveley-a0003a2_uk-robotic-surgery-group-raises-165mn-activity-7110156657711566848-2ydo
They mentioned the work with Intuitive, but CREO also have a deal with a British company - CMR surgical. Much smaller than Intuitive, but arguably nimbler, and closer. Both partnerships are aimed at integrating CREO tools with robot arms, for robot-assisted surgery. Not sure if takeover would make economic sense, as robotics is only one potential revenue source, but if so, Intuitive might face competition. Lot's of "ifs" - this is a speculative one, but even without the robot wars it's interesting, very interesting.
Interesting to see the company issuing new shares for cash. Someone likes it. Useful liquidity
CNN says outbreaks are completely normal, every few years. It decreased during COVID, for obvious reasons, and now it's back. Resistance to antibiotics is a factor, according to the Chinese:
https://edition.cnn.com/2023/12/01/health/mycoplasma-pneumonia/index.html
Governments probably ought to spend far more money on finding cures or partial cures for all of these various respiratory diseases, because everyone would benefit from it, every year, forever.
Analysts have been divided about Sage's prospects following results, but Bank of America pointed out a few days ago that Sage was at a 40% discount to it's American listed rival, Intuit, in terms of EV/EBITDA. America is Sage's largest and fastest growing market, and to them the SP apparently still looks relatively cheap. Maybe UK analysts aren't seeing the big picture?
Results give a weighted average of 1.02 billion shares, elsewhere it's reported as 1.03 billion. The £350m buyback program should therefore bring it very close to a simple billion. Those who don't like sharing remain disgruntled, but fans of round numbers will be dancing in the streets (in a circle)
Interesting strategy casapinos. I don't have any discipline and often don't pay attention (:
Selling always seems a harder decision than it should be - better too early than too late, but there's always a slight irrational regret over either, because timing can never be perfect. "Let's look at what you COULD HAVE won" - emotion trumps logic
Fair enough casapinos. It seems a little odd to keep 30% when cashing out, especially when you stated that you could not see significant SP growth, but clearly you were trimming and hedging rather than out. Congratulations on your success and good luck with your reinvestment